Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins
ABSTRACT The clinical utility of rifamycins against non-tuberculous mycobacterial (NTM) disease is limited by intrinsic drug resistance achieved by ADP-ribosyltransferase Arr. By blocking the site of ribosylation, we recently optimized a series of analogs with substantially improved potency against...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
American Society for Microbiology
2023-10-01
|
| Ráidu: | Microbiology Spectrum |
| Fáttát: | |
| Liŋkkat: | https://journals.asm.org/doi/10.1128/spectrum.01900-23 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|